logo
Unit 50 welcomes feedback on upgrades

Unit 50 welcomes feedback on upgrades

Yahoo20-05-2025

The Teutopolis Unit 50 School Board recently discussed facility upgrades and expansions and how to collect feedback from the community on them.
This summer, the district is using funds from its reserves to complete facility projects such as asbestos abatement work, renovations to the high school and upgrades to office entry points at the high school, junior high and unit office.
These projects are planned to be completed by the beginning of the 2025-2026 school year.
In spring 2026, an expansion to the junior high school will see the addition of both classrooms and restrooms to help accommodate sixth grade students moving from the elementary school to the junior high school. This expansion will also use funds from the district's reserves.
'The planned transition of sixth grade to TJHS for the 2026-27 school year will help the district accommodate its growing student population and set the stage for a long-term facility improvement initiative, potentially beginning as early as 2027-28,' said Superintendent Matthew Sturgeon in the meeting's Media Notes.
Also in spring 2026, there are plans to expand and upgrade the grade school. Plans include restroom upgrades, ADA accessibility improvements and instructional space modernization. Details are still forthcoming while the board acquires additional funding.
To help with the additional funding, the board welcomed a presentation from PMA Securities Public Finance Director Steve Adams during the meeting to assist with financial decision-making.
The board is also in-touch with a communications firm to create a plan to accumulate community feedback for the future projects.
'The board remains committed to responsible financial planning and ensuring that school facilities support student success for years to come,' said Sturgeon in the Media Notes. 'Community members are encouraged to stay informed and participate in upcoming discussions.'
In other news, the board approved the hiring of grade school music teacher Ivy Schmidt, grade school custodian John Westendorf, bus driver Diona Griffy and high school student workers contingent upon their successful completion of background checks, employment history reviews and verification/completion of necessary licensure for the positions. Diversified Occupation Teacher Amanda Hazlett also received a two-day extended contract.
Contracts for high school Principal Tanner Lawson and grade school Principal Sherry Hoehn have been extended through the 2027-28 school year.
The next Unit 50 Board meeting is scheduled for June 16 at 6 p.m.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Yahoo

time19 hours ago

  • Yahoo

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientific Sessions of the American Diabetes Association® (ADA). 'We look forward to presenting work spanning our portfolio to the scientific community at this year's ADA meeting,' said Whit Bernard, Chief Executive Officer of Metsera. 'Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity.' Presentation Highlights MET-097i: A fully biased, ultra-long acting GLP-1 receptor agonist MET-097i is Metsera's fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i's Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a single candidate monthly dose. MET-233i: An ultra-long acting amylin analog MET-233i is Metsera's monthly, ultra-long acting amylin analog. Metsera will present preclinical data, including detailed pharmacokinetic and change in body weight data. Presentation Details: MET-097i: A fully biased ultra-long acting GLP-1 receptor agonist Clinical data Title: A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (788-P)Session: Sunday General Poster SessionPresenter: Robert Stoekenbroek, M.D., Ph.D., Head of Portfolio Strategy at Metsera Time/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 122 Title: Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (753-P)Session: Sunday General Poster SessionPresenter: Steve Marso, M.D., Chief Medical Officer at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 088 Preclinical data Title: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (794-P)Session: Sunday General Poster SessionPresenter: Charlotte Hinds, Ph.D., Senior Director, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 128 Title: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (799-P)Session: Sunday General Poster SessionPresenter: Billy Peter Baxter, Ph.D., Imperial College LondonTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 133 MET-233: An ultra-long acting amylin analog Preclinical data Title: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist (894-P)Session: Sunday General Poster SessionPresenter: James S Minnion, Ph.D., Vice President, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 190 Pipeline programs Preclinical data Title: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice (765-P)Session: Sunday General Poster SessionPresenter: Robert Hansford, Ph.D., Preclinical Research Scientist at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 100 Health Economics and Outcomes Research Title: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset (758-P)Session: Sunday General Poster SessionPresenter: Shannon Armstrong, Vice President, Global Value and Access at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 093 For more information about Metsera's presence at ADA, visit About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 85th Scientific Sessions of the American Diabetes Association® (ADA), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera's business outlined in Metsera's filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera's actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact:Jono EmmettMetseramedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Yahoo

time21 hours ago

  • Yahoo

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientific Sessions of the American Diabetes Association® (ADA). 'We look forward to presenting work spanning our portfolio to the scientific community at this year's ADA meeting,' said Whit Bernard, Chief Executive Officer of Metsera. 'Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity.' Presentation Highlights MET-097i: A fully biased, ultra-long acting GLP-1 receptor agonist MET-097i is Metsera's fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i's Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a single candidate monthly dose. MET-233i: An ultra-long acting amylin analog MET-233i is Metsera's monthly, ultra-long acting amylin analog. Metsera will present preclinical data, including detailed pharmacokinetic and change in body weight data. Presentation Details: MET-097i: A fully biased ultra-long acting GLP-1 receptor agonist Clinical data Title: A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (788-P)Session: Sunday General Poster SessionPresenter: Robert Stoekenbroek, M.D., Ph.D., Head of Portfolio Strategy at Metsera Time/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 122 Title: Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (753-P)Session: Sunday General Poster SessionPresenter: Steve Marso, M.D., Chief Medical Officer at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 088 Preclinical data Title: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (794-P)Session: Sunday General Poster SessionPresenter: Charlotte Hinds, Ph.D., Senior Director, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 128 Title: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (799-P)Session: Sunday General Poster SessionPresenter: Billy Peter Baxter, Ph.D., Imperial College LondonTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 133 MET-233: An ultra-long acting amylin analog Preclinical data Title: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist (894-P)Session: Sunday General Poster SessionPresenter: James S Minnion, Ph.D., Vice President, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 190 Pipeline programs Preclinical data Title: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice (765-P)Session: Sunday General Poster SessionPresenter: Robert Hansford, Ph.D., Preclinical Research Scientist at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 100 Health Economics and Outcomes Research Title: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset (758-P)Session: Sunday General Poster SessionPresenter: Shannon Armstrong, Vice President, Global Value and Access at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 093 For more information about Metsera's presence at ADA, visit About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 85th Scientific Sessions of the American Diabetes Association® (ADA), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera's business outlined in Metsera's filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera's actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact:Jono EmmettMetseramedia@

TRON Jumps After Sun's Tweet, Network Volume Hits All-Time High
TRON Jumps After Sun's Tweet, Network Volume Hits All-Time High

Yahoo

timea day ago

  • Yahoo

TRON Jumps After Sun's Tweet, Network Volume Hits All-Time High

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. TRON (CRYPTO: TRX) is trading at $0.2688, after a price spike of 4.2%. According to CoinMarketCap, the surge came within two hours following a tweet from TRON founder, Justin Sun, on June 3, making TRX the 9th largest crypto. Sun tweeted 'looking forward to it', which reflected interest generated by his social media activity. According to BeInCrypto, market interest is influenced by TRON's network performance. TRX recorded a new all-time high in monthly transfer volume in May 2025. Per TradersUnion, analysts reported that 490.3 billion TRX were transferred, which is equivalent to $132.4 billion at a price of $0.27. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. New to trading crypto? on Coinbase. The volume was a 34% increase from the 362.92 billion transferred in April 2025. TRON overtook Cardano (CRYPTO: ADA) in May to become the 9th largest cryptocurrency by market capitalization. TRON's market cap climbed to nearly $26 billion, while Cardano's dropped to $23 billion. The ranking grew as TRX's price rose 8.8% in May, per BeInCrypto. According to The Tradable, TronDAO initiated a series of unusual TRX movements, leading to community discussions about a possible sell-off. 10 transactions moved a total of 8,777,561,962 TRX to unknown wallets. TronDAO has not provided explanations for these transfers. According to a 45% surge was observed in large TRX transactions within a 24-hour period, amounting to over $215 million. TRX price is in the $0.27-$0.275 range. The consolidation indicates a mismatch between selling and buying pressure. It places TRX in a critical zone where its direction could change quickly based on market conditions. Traders should note potential false breakout signals above the $0.274 mark. The $0.255 area could become a zone for short-term buying if a positive price reaction occurs. Sun's tweet and May's record network activity offer a potentially bullish backdrop, with some forecasts targeting $1 per token. Per CoinJournal, TRX requires a 270% price increase from its current level to reach the $1 mark. Growing network activity and rising adoption indicate a potential for continued upward price movement for TRX in the near to medium term. The unexplained large TronDAO transfers and current price consolidation require close observation. More Opportunities: Grow your IRA or 401(k) with Crypto – . Trade, earn, and grow your crypto portfolio with — . Image: Shutterstock This article TRON Jumps After Sun's Tweet, Network Volume Hits All-Time High originally appeared on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store